Brain Tumours

Pituitary

Study

41’000 patients/9 studies (pituitary- hypothalamic tumors)

10y TPFS 70% vs. 74% (NS)

NFPA

TP not affected by GHR (Significant factor: residual tumor, RT) GH not predictor of tumor progression after ajusting for gender, resction, age, invasion cav. Sinus)

Craniopharyngioma

NFPA

No difference observed

Secondary tumors in patients with RT +/- GHR (match pait analysis)

03/01/13